tadalafil/dutasteride (DKF-313) / Dongkook Pharma - LARVOL DELTA

Sarcopenia is a factor for unsatisfied medical treatment of lower urinary tract symptoms in elderly men aged 75 years or older – analysis using SARC-F - (AUA 2024) - "All patients received α1 blocker or tadalafil... Sarcopenia screened by SARC-F is a significant factor for unsatisfied medical treatment of LUTS in elderly men aged 75 years or older."

Clinical • Overactive Bladder • Sarcopenia

DKF-313-P3: Efficacy and Safety of DKF-313 in Patients With Benign Prostatic Hyperplasia (clinicaltrials.gov) - P3 | N=667 | Completed | Sponsor: Dongkook Pharmaceutical Co., Ltd. | Recruiting ➔ Completed

Trial completion • Benign Prostatic Hyperplasia

Use of 5-ARIs May Decrease Bladder Cancer Risk (Renal and Urology News) - "'Among studies that sought to determine whether 5-ARIs have a role in bladder cancer prevention, some demonstrated positive correlation and some negative co-investigator Blayne Welk, MD, MSc...noted in an interview. Our study examined compliance to treatment and is an important milestone in this field. Further research is needed to better understand the findings.'"

Interview

Efficacy of a combination of dutasteride, tadalafil, and solifenacin in the treatment of previously unsuccessful patients. (PubMed, Asian J Urol) - "The total assessment of symptoms of hyperactivity significantly decreased in Group C according to OABq data after the 4th week of the study (17.5 points vs. 26.1 points, p<0.05) and remained below the baseline until the end of the study (15.2 points). The simultaneous administration of standard doses of dutasteride, solifenacin, and tadalafil for 3 months is safe, effective, and can be recommended for patients with BPH to reduce symptoms of obstruction and hyperactivity of the bladder and maintain sexual function."

Journal • Benign Prostatic Hyperplasia • Overactive Bladder

DKF-313-P3: Efficacy and Safety of DKF-313 in Patients With Benign Prostatic Hyperplasia (clinicaltrials.gov) - P3; N=654; Recruiting; Sponsor: Dongkook Pharmaceutical Co., Ltd.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Benign Prostatic Hyperplasia

Safety and Pharmacokinetic Characteristics of DKF-313 (clinicaltrials.gov) - P1; N=54; Completed; Sponsor: Dongkook Pharmaceutical Co., Ltd.; Recruiting ➔ Completed

Clinical • Trial completion • Benign Prostatic Hyperplasia

DKF-313-P3: Efficacy and Safety of DKF-313 in Patients With Benign Prostatic Hyperplasia (clinicaltrials.gov) - P3; N=654; Not yet recruiting; Sponsor: Dongkook Pharmaceutical Co., Ltd.

Clinical • New P3 trial • Benign Prostatic Hyperplasia